Trial Profile
Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Advanced Non-Clear Cell Renal Cell Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 May 2013
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pemetrexed (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 06 Apr 2012 Primary endpoints added as reported by ClinicalTrials.gov.
- 25 Oct 2011 Planned end date changed from 1 Dec 2012 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 25 Oct 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.